ALFA Finder| Revenue guidance | 29.0% → 39.0% Raised by 10.0 percentage points |
|---|---|
| Management target | Revenue 39.0% FY27 |
| Revenue growth | 45.7% YoY in Q1FY27. |
|---|---|
| Margins | EBITDA margin improved to 25.3% in Q1FY27. |
| Demand visibility | Strong visibility in regulated markets; 700+ filings. |
| Management confidence | High; raised guidance for FY27. |
Growth
Q1FY27 revenue hit INR 162.4 Cr (+45.7% YoY); PAT surged 119.3% YoY to INR 25.7 Cr.
Outlook
FY27 revenue guidance raised to 39%+ growth. Aiming for INR 1,000+ Cr revenue by FY29 with 30%+ EBITDA margin.
Risks
High working capital cycle (161 days) and ongoing heavy capex for Biologics and Hormone facilities.
Last quarter's promises, checked
Delivered
- FY26 Revenue INR 503 Cr → delivered INR 503 Cr (= BEAT)
- FY26 PAT INR 67 Cr → delivered INR 67 Cr (= BEAT)
- Q1FY27 Revenue ~INR 150-160 Cr → delivered INR 162.4 Cr (= BEAT)
Partly delivered
- Cash conversion cycle 170 days → delivered 161 days (= PARTIAL)
Investor Presentation filed with BSE, NSE: KPL. Summary written with AI assistance from the document.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,020.00
- Market cap
- ₹4,171 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 51.5×Sector 43.8×
- Promoter holding
- 54.86%+0.00% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Board Meeting Date
Kwality Pharmaceuticals will hold a board meeting on November 12, 2026. The board will consider and approve unaudited financial results for the quarter and half-year ended September 2026.
Kwality Pharmaceuticals Business Update
Kwality Pharmaceuticals secured EU-GMP approval from Hungary for its Cephalosporin and Oncology facilities. This expands its EU-approved manufacturing footprint and positions it for global licensing opportunities.
Kwality Pharmaceuticals Other Announcement
Kwality Pharmaceuticals Ltd filed its shareholding pattern for the quarter ended September 30, 2026, as required by SEBI regulations.
Kwality Pharmaceuticals Capacity Expansion
Kwality Pharmaceuticals acquired 4 acres adjacent to its Amritsar plant to build a fully automated facility with 10+ production lines. Completion is targeted by Q4 FY2028 with full operations by Q2 FY2029.
- Execution
- Completion by Q4 FY2028; full operations by Q2 FY2029
- manufacturing production lines (injectable + oral solid + ophthalmic)
- 10 production lines
Kwality Pharmaceuticals Management Change
Kwality Pharmaceuticals has regularized the appointment of Mr. Swanith Kapoor as Independent Director and reappointed Mr. Aditya Arora as Whole Time Director for five years.
Kwality Pharmaceuticals Annual General Meeting
Kwality Pharmaceuticals Limited conducted its 43rd Annual General Meeting on August 31, 2026, via video conferencing. The meeting covered routine shareholder resolutions and director re-appointments.